Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Steele

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Magnetic Resonance in Medicine|May 31, 2024
Tricuspid valve flow measurement using a deep learning framework for automated valve-tracking 2D phase contrastJérôme Lamy, Ricardo A Gonzales, Jie Xiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trialsDean A Fennell, Amit Parmar, Jonathan Shamash, et al.
European Journal of Human Genetics : EJHG|August 22, 2023
Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndromeFiona Lalloo, Anju Kulkarni, Cindy Chau, et al.
JTO Clinical and Research Reports|September 30, 2021
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance MechanismsPeter W Szlosarek, Melissa M Phillips, Iuliia Pavlyk, et al.
Pharmacological Reports : PR|May 17, 2023
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaMelissa M Phillips, Iuliia Pavlyk, Michael Allen, et al.
Pharmacological Reports : PR|April 3, 2023
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaMelissa M Phillips, Iuliia Pavlyk, Michael Allen, et al.
Lancet (London, England)|May 20, 2008
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trialMartin F Muers, Richard J Stephens, Patricia Fisher, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2012
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesotheliomaJaine K Blayney, Giovanni L Ceresoli, Bruno Castagneto, et al.
Thorax|February 16, 2018
British Thoracic Society Guideline for the investigation and management of malignant pleural mesotheliomaIan Woolhouse, Lesley Bishop, Liz Darlison, et al.
BMJ Open Respiratory Research|March 14, 2018
BTS guideline for the investigation and management of malignant pleural mesotheliomaIan Woolhouse, Lesley Bishop, Liz Darlison, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Magnetic Resonance in Medicine|May 31, 2024
Tricuspid valve flow measurement using a deep learning framework for automated valve-tracking 2D phase contrastJérôme Lamy, Ricardo A Gonzales, Jie Xiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trialsDean A Fennell, Amit Parmar, Jonathan Shamash, et al.
European Journal of Human Genetics : EJHG|August 22, 2023
Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndromeFiona Lalloo, Anju Kulkarni, Cindy Chau, et al.
JTO Clinical and Research Reports|September 30, 2021
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance MechanismsPeter W Szlosarek, Melissa M Phillips, Iuliia Pavlyk, et al.
Pharmacological Reports : PR|May 17, 2023
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaMelissa M Phillips, Iuliia Pavlyk, Michael Allen, et al.
Pharmacological Reports : PR|April 3, 2023
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaMelissa M Phillips, Iuliia Pavlyk, Michael Allen, et al.
Lancet (London, England)|May 20, 2008
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trialMartin F Muers, Richard J Stephens, Patricia Fisher, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2012
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesotheliomaJaine K Blayney, Giovanni L Ceresoli, Bruno Castagneto, et al.
Thorax|February 16, 2018
British Thoracic Society Guideline for the investigation and management of malignant pleural mesotheliomaIan Woolhouse, Lesley Bishop, Liz Darlison, et al.
BMJ Open Respiratory Research|March 14, 2018
BTS guideline for the investigation and management of malignant pleural mesotheliomaIan Woolhouse, Lesley Bishop, Liz Darlison, et al.
Pageof 4